[MCQs] Chronic Myeloid Leukemia (CML) – Part 2

I. Start the exam by click the “Start” button

See all quizzes of  the Chronic Myeloid Leukemia (CML)  at here:

Chronic Myeloid Leukemia (CML) – Part 1 | Chronic Myeloid Leukemia (CML) – Part 2

II. Preview all questions below

1. Sokal index staging system in CML includes all except ?
A. Percentage of circulating blasts
B. Spleen size
C. Hemoglobin
D. Platelet count
2. Sokal index staging system in CML includes all except ?
A. Cytogenetic clonal evolution

B. Age
C. Sex
D. Percentage of circulating blasts

3.  Hasford staging system in CML does not include which of the following ?
A. Cytogenetic clonal evolution
B. Age
C. Spleen size
D. Percentage of circulating blasts

4.  CML is characterized by ?
A. Progressive granulocytosis
B. Marrow hypercellularity
C. Splenomegaly
D. All of the above

5.  In CML treatment, complete hematologic remission means ?
A. WBC <10,000 / µL
B. Normal blood morphology, hemoglobin & platelet counts
C. Disappearance of splenomegaly
D. All of the above

6.  In CML treatment, complete cytogenetic remission means ?
A. No bone marrow metaphases with t(9;22)
B. < 10% bone marrow metaphases with t(9;22)
C. 1 – 35% bone marrow metaphases with t(9;22)
D. 36 – 85% bone marrow metaphases with t(9;22)

7.  Which of the following drugs is effective in treatment of CML ?
A. Imatinib mesylate
B. IFN-
C. Hydroxyurea
D. All of the above

8. Function of protein kinase enzymes is to transfer ?
A. Phosphate from ATP to specific amino acids
B. Adenosine from ATP to specific amino acids
C. Phosphate & adenosine from ATP to specific amino acids

D. None of the above

9. Which of the following are subfamilies of protein kinases ?
A. Protein serine – threonine kinases
B. Protein tyrosine kinases
C. A+B
D. None of the above

10.  Which of the following are protein kinases ?
A. BCR-ABL
B. Protein kinase C
C. Epidermal growth factor receptor
D. All of the above

11. The tyrosine kinase inhibited by imatinib is ?
A. c-kit
B. Epidermal growth factor receptor FLT1
C. Epidermal growth factor receptor FLT3
D. All of the above

12.  Imatinib mesylate is a specific inhibitor of which of the following TKs ?
A. ABL, ABL-related gene product (ARG)
B. c-KIT
C. PDGF receptor (PDGFR)
D. All of the above

13. The proto-oncogene c-kit is expressed in ?
A. Gastrointestinal stromal tumors
B. Mast-cell tumors
C. Neuroblastoma
D. All of the above

14.  Imatinib has effective activity in cases of ?
A. CML
B. Gastrointestinal stromal tumors (GIST)
C. Chronic myelomonocytic leukemia (CMML)
D. All of the above

15. Imatinib mesylate is most effective in ?
A. Chronic-phase CML
B. Accelerated phase CML
C. Blast-crisis phase CML
D. All of the above

16. Treatment of CML with Imatinib mesylate is currently recommended for ?
A. 1 year
B. 3 years
C. 5 years
D. Life long

17.  Which of the following statements about Imatinib mesylate is false ?
A. Imatinib is administered orally
B. Dose is 400 mg per day
C. Most common hematologic side effect is
myelosuppression
D. None of the above

18. What dose of Imatinib mesylate is ineffective and may lead to development of resistance ?
A. < 300 mg / day
B. < 400 mg / day
C. < 500 mg / day
D. < 600 mg / day

19.  Which of the following is the mechanism of resistance to imatinib ?
A. Gene amplification
B. Mutations at the kinase site
C. Enhanced expression of multidrug exporter proteins
D. All of the above

20.  CML with the T315I mutation is resistant to ?
Harrison’s 18th Ed. 916
A. Imatinib
B. Nilotinib
C. Dasatinib
D. All of the above

21.  Therapy with which of the following in CML does not induce cytogenetic remission ?
A. Imatinib mesylate
B. IFN-
C. Hydroxyurea
D. All of the above

22.  Therapy with which of the following in CML does not induce rapid hematologic responses ?
A. Imatinib mesylate
B. IFN-
C. Hydroxyurea
D. All of the above